Patents Assigned to Cardiora Pty Ltd.
  • Milrinone controlled-release formulation
    Patent number: 10736853
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 11, 2020
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Milrinone controlled-release formulation
    Patent number: 10537527
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: January 21, 2020
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Uses of milrinone controlled-release formulation
    Patent number: 10517833
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: December 31, 2019
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Method of treating heart failure with preserved ejection fraction by administering milrinone
    Patent number: 10493067
    Abstract: The present invention relates to methods of treating subjects having heart failure with preserved ejection fraction (HFpEF) with a sustained-delivery formulation of cardiotonic 5-(pyridinyl)-2(1H)-pyridinone compounds.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: December 3, 2019
    Assignee: CARDIORA PTY LTD.
    Inventor: David Kaye
  • Milrinone controlled-release formulation
    Patent number: 10137093
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: November 27, 2018
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan